Datapoint: Lilly Scores UC Nod for Omvoh

After a long wait and previous rejection, the FDA on Oct. 26 approved Lilly’s Omvoh for the treatment of moderately to severely active ulcerative colitis (UC) in adults. The drug is the first interleukin-23p19 (IL-23p19) antagonist approved to treat UC, and is first administered via infusions, then self-injections as maintenance requires. Among the most advantaged ulcerative colitis therapies covered under the medical benefit are tumor necrosis factor-alpha blockers, such as Johnson & Johnson’s Remicade, which holds covered or better status for 94% of insured lives, Merck’s Remicade biosimilar Renflexis (92%) and Pfizer’s Remicade biosimilar Inflectra (91%).

SOURCE: MMIT Analytics, as of 10/30/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 21

Datapoint: Aetna Shut Out of Medicaid Contract Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 20

Datapoint: FDA Expands Otezla’s Psoriasis Label

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: Cigna, Oscar to End Small Group Partnership

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today